|
Volume 16, Issue 5, May 2009, in PDF
|
   |
Article: 602
U.S. Sites Rate Novo Nordisk, Novartis and Eisai as Top Sponsors in 2009
Results of the CenterWatch 2009 Survey of Investigative Sites in the U.S. are in.
Article: 603
CROs Going Private
Three large global CROs— Quintiles, PRA and Pharma- Net—have goneprivate inrecent years. Though each had company- specific reasons for themove, other large CROsmay also want the freedom to pursue a longterm strategic vision without worrying about the quarterly reporting demands of Wall Street.
Article: 604
Inspection Programs Move from Retrospective to Risk-Based in Europe
Until the Clinical Trials Directive (2001/20/EC) went into effect five years ago, Good Clinical Practice (GCP) inspections were conducted retrospectively, often voluntarily and only with marketing authorization (MA) application.
Article: 605
Eye On: Gastrointestinal Diseases
Gastrointestinal diseases may affect different sites in the entire digestive system from the mouth to the esophagus, stomach, small intestine, colon, rectum and anus.
Price: $59.00
|